Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Hansa Biopharma
  4. Hansa Biopharma — Maj 2023

Hansa Biopharma — Maj 2023

Planlagt Fastgjort Låst Flyttet Hansa Biopharma
69 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    rolling
    wrote on sidst redigeret af
    #13

    Er det i dag der kommer nyt fra sarepta ???

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #14

      Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy

      Link Preview Image
      Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle

      Shares of SRPT stock launched Monday after FDA advisors voted late Friday in support of a highly anticipated gene therapy from Sarepta.

      favicon

      Yahoo Finance (finance.yahoo.com)

      1 Reply Last reply
      0
      • exitnuE Offline
        exitnuE Offline
        exitnu
        wrote on sidst redigeret af
        #15

        FDA advisors will vote Friday on the approvability of Sarepta's highly anticipated gene therapy. SRPT stock was halted ahead of the meeting.

        1 Reply Last reply
        0
        • R Offline
          R Offline
          rolling
          wrote on sidst redigeret af
          #16

          takker Exitnu

          1 Reply Last reply
          0
          • exitnuE Offline
            exitnuE Offline
            exitnu
            wrote on sidst redigeret af
            #17

            ILM 🙂

            1 Reply Last reply
            0
            • M Offline
              M Offline
              MBCruise
              wrote on sidst redigeret af
              #18

              Tak for link Exitnu - Analytikerne lyder ikke så positive på udfaldet (i linket)

              1 Reply Last reply
              0
              • exitnuE Offline
                exitnuE Offline
                exitnu
                wrote on sidst redigeret af
                #19

                Selv tak 🙂

                1 Reply Last reply
                0
                • exitnuE Offline
                  exitnuE Offline
                  exitnu
                  wrote on sidst redigeret af
                  #20

                  UPDATE 1-FDA advisers weigh Sarepta's Duchenne gene therapy

                  Link Preview Image
                  UPDATE 4-US FDA advisers narrowly back Sarepta's Duchenne gene therapy for accelerated approval

                  Advisers to the U.S. Food and Drug Administration on Friday narrowly recommended that the agency grant accelerated approval to Sarepta Therapeutics Inc's first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD). Tabassum Ahsan, chair of the panel and vice president of cell therapy operations at California's City of Hope, said she was "very much on the edge" but ended up voting yes.

                  favicon

                  Yahoo Finance (finance.yahoo.com)

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #21

                    Sarepta: pt. køb i kurs 110,01 & salg i kurs 160 🙂

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #22

                      Aktien er pt. paused. Det skal vi lige huske. 🙂

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #23

                        FDA says there isn't persuasive evidence that expression of Sarepta's micro-dystrophin correlates to an improvement in NSAA score.

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #24

                          https://www.fda.gov/media/168021/download

                          1 Reply Last reply
                          0
                          • exitnuE Offline
                            exitnuE Offline
                            exitnu
                            wrote on sidst redigeret af
                            #25

                            Max Bayer (staff writer @FierceBiotech covering new drug development)

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #26

                              FDA presentation has concluded. Q&A now. https://twitter.com/maxonwifi/status/1657090567497474050

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #27

                                Logger ud - god aften til ALLE!

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #28

                                  Tak exitnu...Jeg følger Q&A. Umiddelbart ser det ikke godt ud for det videre forløb for Sarepta.

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #29

                                    FDA advisors say the benefit-risk profile of SRP-9001 DOES support accelerated approval. The votes:
                                    Yes: 8

                                    No: 6

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #30

                                      FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy

                                      Just a moment...

                                      favicon

                                      (www.fiercebiotech.com)

                                      1 Reply Last reply
                                      0
                                      • exitnuE Offline
                                        exitnuE Offline
                                        exitnu
                                        wrote on sidst redigeret af
                                        #31

                                        "Experts from the Cellular, Tissue, and Gene Therapies Advisory Committee narrowly voted 8 to 6 that the benefit-risk profile of SRP-9001 was strong enough to support accelerated approval even as questions about the gene therapy's efficacy linger."

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #32

                                          ""I think we owe it to the patients to help them intervene," said committee member and consumer representative Kathleen O’Sullivan-Fortin, who voted in favor. Others expressed confidence in the safety profile of the gene therapy even amid concerns about the efficacy."

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper